{
    "nct_id": "NCT06005974",
    "official_title": "A Phase 2, Open Label Study of REC-4881 in Participants with Unresectable Locally Advanced or Metastatic Cancer with AXIN1 or APC Mutation",
    "inclusion_criteria": "1. 55 years of age or older with histologically-confirmed unresectable, locally advanced, or metastatic solid tumor with AXIN1 or APC mutation. If a participant has colorectal cancer, then they must be RAS / RAF wild type to enroll into the APC mutant cohort\n2. Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment, or in the opinion of the Investigator have been considered ineligible for standard therapy\n3. Measurable disease at baseline per RECIST 1.1 criteria\n4. Eastern Cooperative Oncology Group (ECOG) performance status â‰¤ 1\nHealthy volunteers allowed\nMust have minimum age of 55 Years",
    "exclusion_criteria": "1. Received treatment with another mitogen-activated protein kinase (MEK) inhibitor within two months of first dose of REC-4881\n2. Left ventricular ejection fraction (LVEF) <50% as measured by echocardiogram (ECHO) or multigated acquisition (MUGA) scan",
    "miscellaneous_criteria": ""
}